Explore the Agenda

8:00 am Check-In & Light Breakfast

8:45 am Chair’s Opening Remarks

VP, Head of Chemistry, Rapafusyn Pharmaceuticals

Harnessing Novel E3 Ligases for Molecular Glue Programs: Revealing New Targets & Accelerating Translation

9:00 am Harnessing Novel Molecular Glue Degraders to Target K-Ras Mutants & Overcome Resistance Pathways

Chief Executive Director, HB Therapeutics, Inc.
  • Engaging a novel ligase for targeted degradation to selectively degrade mutant K-Ras while sparing the wild-type protein
  • Dual-target effect via co-degradation of Seraph, addressing the major resistance pathway in K-Ras-driven cancers and creating a unique therapeutic opportunity
  • Structural insights into ternary complex formation, revealing how the molecular glue stabilizes interactions between the ligase and target proteins, guiding next-generation degrader design

9:30 am Expanding the Molecular Glue Toolbox: Harnessing Novel E3 Ligases

Senior Scientist, Stanford University
  • Explore innovative strategies to harness non-Cullin-based degradation mechanisms for targeted protein degradation
  • Leverage structural insights to improve prediction accuracy and guide rational discovery of novel ligase-glue pairs
  • Understand how bold discovery strategies and broader search spaces can accelerate breakthroughs in molecular glue therapeutics

10:00 am Harnessing Novel E3 Ligases to Unlock New Opportunities in Molecular Glue Drug Discovery

Principal Investigator, University of Toronto
  • Leveraging a large portfolio of novel E3 ligases in diverse screening campaigns (traditional screening, DEL, ML-based approaches, and ASMS) to expand the landscape of glue discovery
  • Identifying hits that engage substrate recognition components of E3 ligases, supported by structural insights and mechanistic validation
  • Highlighting case studies, including FBXO22 and a deubiquitinase–E3 ligase axis, as emerging examples of potential molecular glue mechanisms with translational relevance

10:30 am Morning Break & Networking

Supercharging Molecular Glue Discovery with High-Sensitivity Assays, Tailored Libraries & Integrated PPI Technologies to Strengthen Hit Detection & Guide Lead Advancement

11:30 am Advancing Molecular Glue Discovery through a Positive-Signal Bacterial Screening Platform

Director of R&D, Coltac Therapeutics
  • Combining in-silico with the power of our bacteria-based, synthetic positive selection screening system for new molecular glues
  • Program insights covering oncology and non-oncology programs, with focus on ligase diversity, target specificity, and optimization process
  • Future directions that include expanding beyond degraders to explore non-degraders and PPI modulators, supporting both scientific advancement and company growth strategy

12:00 pm A Screening-First Approach to Molecular Glue Discovery: Unlocking Cooperativity Without Structural Data

Senior Vice President of Platform Technology, Parabilis Medicines
  • Unlocking glue discovery without relying on structural information, opening new possibilities for difficult targets
  • Leveraging two tandem 100M+ member library screens to move from initial binders to true cooperative molecular glues
  • Ensuring conditional, cooperative activity that reduces off-target risks and enables safer non-degradation strategies

12:30 pm Accurate Prediction of Tractable Ternary Complexes & Optimised Molecular Glues for Any Protein-Protein Interaction

Chief Executive Officer, Ternary Therapeutics
  • An overview of Ternary’s end-to-end molecular glue design platform
  • Revealing in vitro validation of the platform
  • Exploring current limitations to AI-enabled molecular glue design

1:00 pm Lunch Break & Networking

2:00 pm Biology-First Discovery of Non-Degrading Molecular Glues Targeting E2 Enzymes for Neurodegeneration

Chief Technology Officer, Head of Research & Development Site, BPGBio Inc.
  • Leveraging AI-driven biology discovery to identify ubiquitin-conjugating enzymes (E2s) as novel therapeutic target
  • Demonstrating a unique mechanism of action by locking ubiquitin to E2 enzymes, preventing discharge, inhibiting enzyme function, and triggering autophagy to clear mutant huntingtin
  • Advancing lead optimization efforts with the goal of progressing to animal proof-ofconcept studies for neurodegenerative proteinopathies

2:30 pm Platform for the Discovery of Molecular Glues

  • Lighting up molecular glue biology in real time – we developed a NanoBRET-powered high-throughput platform that directly visualizes E3 ligase–substrate interactions in live cells, transforming molecular glue discovery from serendipity to systematic science
  • From mechanism to molecules – by capturing dynamic CRBN–CUL4A and DCAF15–CUL4A assemblies with sensitive NanoBRET proximity assays, this platform delivers both mechanistic insight and a scalable engine to uncover new degraders across the CRL family
  • Expanding the degradable proteome – applying this approach, we identified novel glue candidates and validated CMC2 as a DCAF15-recruiting substrate for proof-of-concept degradation, demonstrating a powerful strategy to accelerate glue discovery and guide next-generation targeted protein degradation therapies

Highlighting Clinical Performance of Molecular Glues to Advance Development & Bring Effective Therapies to Patients Faster

3:00 pm RIPTACs: Harnessing Cooperative PPIs to Drive Stable Ternary Complexes & Clinical Promise

Vice President, Head of Chemistry, Halda Therapeutics, LLC
  • Hypothesis driven approach to achieve novel induced proximity pairings with unique mechanism-of-action
  • Targeting a cooperative ternary complex to achieve exquisitely selective functional impact in oncology
  • Driving translational progress through in vitro, in vivo, and toxicology studies, to emerging clinical data that highlight RIPTACs’ therapeutic promise

3:30 pm Chair’s Closing Remarks

VP, Head of Chemistry, Rapafusyn Pharmaceuticals

3:45 pm End of 4th Molecular Glue Drug Development Summit